Home Newsfeeds Raymond James Maintains Strong Buy on Aveanna Healthcare Hldgs, Lowers Price Target to $6

Raymond James Maintains Strong Buy on Aveanna Healthcare Hldgs, Lowers Price Target to $6

Raymond James analyst John Ransom maintains Aveanna Healthcare Hldgs (NASDAQ:AVAH) with a Strong Buy and lowers the price target from $8 to $6.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Raymond James analyst John Ransom maintains Aveanna Healthcare Hldgs (NASDAQ:AVAH) with a Strong Buy and lowers the price target from $8 to $6.

Goldman Sachs Downgrades NGM Biopharmaceuticals to Neutral, Lowers Price Target to $4

By Benzinga Newsdesk

October 18, 5:12 AM

Goldman Sachs analyst Paul Choi downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Neutral and lowers the price target from $29 to $4.

NGM

Goldman Sachs Maintains Buy on uniQure, Raises Price Target to $57

By Benzinga Newsdesk

November 23, 10:55 AM

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Buy and raises the price target from $47 to $57.

QURE

News

Beyond Air Licenses Commercial Rights To Selective Neuronal Nitric Oxide Synthase Inhibitors For The Treatment Of Autism Spectrum Disorder From Hebrew University Of Jerusalem

By Benzinga Newsdesk

June 15, 4:09 PM

Hebrew University's preclinical results recently published in Advanced Science show a reversal of the molecular, synaptic and behavioral autism spectrum disorder (ASD) phenotypes Plan to initiate a first-in-human

XAIR

News

Jim Cramer Disses Tesla Cybertruck: Who Built That Monstrosity? Fred Flintstone?

By Adam Eckert

July 11, 12:44 PM

Earlier this year, Jim Cramer called the Tesla Inc (NASDAQ: TSLA) Cybertruck a "toy for Elon Musk fanboys" and one of the u

Raymond James Maintains Strong Buy on Aveanna Healthcare Hldgs, Lowers Price Target to $6

Related Posts

Goldman Sachs Downgrades NGM Biopharmaceuticals to Neutral, Lowers Price Target to $4

Goldman Sachs Maintains Buy on uniQure, Raises Price Target to $57

Beyond Air Licenses Commercial Rights To Selective Neuronal Nitric Oxide Synthase Inhibitors For The Treatment Of Autism Spectrum Disorder From Hebrew University Of Jerusalem

Jim Cramer Disses Tesla Cybertruck: Who Built That Monstrosity? Fred Flintstone?